Participant Diversity in United States Randomized Controlled Trials of Antibacterials for Staphylococcus aureus Infections, 2000–2021
Kwon J, Pelletiers W, Peña J, van Duin D, Ledbetter L, Baum K, Ruffin F, Knisely J, Bizzell E, Fowler V, Chambers H, Pettigrew M. Participant Diversity in United States Randomized Controlled Trials of Antibacterials for Staphylococcus aureus Infections, 2000–2021. Clinical Infectious Diseases 2024, 79: 141-147. PMID: 38306502, PMCID: PMC11259209, DOI: 10.1093/cid/ciae049.Peer-Reviewed Original ResearchMethicillin-resistant S. aureusRandomized controlled trialsPhase 2/3 trialsPhase 4 trialIncidence of methicillin-resistant S. aureusTreat Staphylococcus aureus infectionsStaphylococcus aureus infectionStandard of carePercentage of study participantsIncidence ratiosClinical trialsEthnicity of participantsControlled trialsStandardized reporting methodsBlack participantsStudy sizeInfectionDisease populationTrialsStudy participantsAntibacterial agentsIncreased recruitmentIndustry sponsorshipEthnicity dataSex